The company's lead antibody program (TRIV-509) targets kallikreins 5 and 7 (KLK5/7) and directly impacts skin barrier function, inflammation, and itch – providing a meaningful and much needed potential treatment option for patients with atopic dermatitis and other barrier disorders. Triveni hopes to advance TRIV-509 into the clinic in the first half of 2025 and bring second-generation combination approaches into the clinic in 2026.